That is also one of my favorites - to think we are working toward the elimination of the condition is astounding.  We're not going for taking market share from existing standards of care - we are eliminating the need for 'care'.  I'm not so sure the investing world realizes this yet.  (and don't, anyone, give me that BS about big pharma will never let that happen - they love everlasting 'care'. If they sweep this under the rug for say a $5B acquisition of our big P, I'll still be happy)  Preclinical results had no reoccurrence of the disease... um... do I have enough shares yet?